When administered soon after the onset of acute ischemic stroke, current approved treatments for the condition can dramatically improve patient outcomes. However, not all patients are cured, and approved treatments also carry risks, including cerebral hemorrhage or bleeding into the brain.
Now, a novel second-generation variant of a naturally occurring human protein – known as 3K3A-APC – is poised to change that. The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, has awarded a $4 million grant as the first portion of what is anticipated to be a $30 million award over six years to the Keck School of Medicine of USC to conduct a pivotal phase 3 clinical trial of the experimental drug.
To continue reading this story, click here.